The NeoALTTO trial showed that dual HER2 blockade nearly doubles the rate of pathologic complete response ( pCR) in patients with primary HER2-positive breast cancer. However, this did not translate into a higher rate of breast-conserving surgery (BCS).
introduction Data from randomized trials have shown no difference in survival between breast cancer patients receiving adjuvant or neoadjuvant primary systemic therapy [1, 2] . While to date the conventional sequence is to administer treatment in the postoperative setting, the neoadjuvant approach has been endorsed by several groups and experts for a wide variety of reasons [3, 4] . Down-staging of the tumor resulting in an increase in breast conservation rates remains one of the most important advantages of the neoadjuvant approach [5] . However, even in patients who are eligible for breast conservation at diagnosis, the neoadjuvant setting can still offer potential advantages, such as determining the sensitivity of the tumor to systemic therapy and possible elimination of micrometastases [6] .
Pathological complete response ( pCR) to chemotherapy has been identified as a reliable surrogate marker for long-term survival [7] [8] [9] , particularly in patients with HER2 amplification [9] . The addition of the HER2-targeted agent, trastuzumab, to chemotherapy has been shown to be associated with a higher rate of pCR compared with chemotherapy alone [10] [11] [12] . This high pCR rate further translated into an improvement in disease-free survival [10] . This has resulted in using the neoadjuvant setting to gain relatively fast insights into the efficacy of HER2-targeted agents in the primary setting.
Recently, four trials namely the NeoAdjuvant Lapatinib and/ or Trastuzumab Treatment Optimization (NeoALTTO) [13] , the neoadjuvant study of pertuzumab and herceptin in an early regimen evaluation [14] , the National Surgical Adjuvant Breast and Bowel Project-B41 [15] and the trastuzumab plus pertuzumab in neoadjuvant HER2-positive breast cancer (TRYPHAENA) [16] reported on the value of dual HER2 blockade in primary HER2-positive breast cancer. These studies consistently showed that the addition of dual HER2 blockade to chemotherapy significantly improves pCR rates compared with the same regimen in combination with trastuzumab alone.
In the NeoALTTO trial [13] , although dual HER2 blockade with lapatinib and trastuzumab in combination with weekly paclitaxel nearly doubled the rate of pCR, compared with paclitaxel combined with either drug alone, this high pCR rate did not translate into a higher rate of breast-conserving surgery (BCS), which was around 40% across the three treatment arms. This observation was rather surprising. Hence, we conducted this sub-study to investigate the different factors that may have affected the choice of surgical modality in patients enrolled in the NeoALTTO trial.
patients and methods
NeoALTTO is a randomized, phase III, multicenter, international trial in which patients with primary HER2-positive breast cancer, and tumor size >2 cm were randomizly assigned to either lapatinib, trastuzumab or their combination for 6 weeks followed by the addition of paclitaxel for 12 more weeks before breast surgery [13] . All patients were evaluated according to whether or not they were eligible for BCS before initiation of neoadjuvant therapy (will be referred to as 'planned surgery at diagnosis'). All patients were prospectively subjected to clinical examinations at baseline, weeks 2, 4, 6 and weekly afterwards until surgery. As per protocol, all patients were also subjected to either mammography or echography at baseline, week 6 and after completion of neoadjuvant therapy (i.e. before surgical intervention). This information was prospectively collected on the case report form.
Following surgery, all patients received three cycles of 5-fluorouracil, epirubicin 100 mg/m 2 and cyclophosphamide (i.e. FEC100) followed by the continuation of the same HER2-targeted therapy that was administered in the neoadjuvant setting to complete a total duration of 1 year. Further information on the trial including eligibility criteria, statistical analysis and the results is described in detail elsewhere [13] . The primary end point of the main study was the rate of pCR defined as the absence of invasive tumor cells in the breast at the time of surgery [17] . The ethics committees of all participating sites approved the study and an informed consent was obtained from all patients at study entry. This substudy was approved by the NeoALTTO executive committee.
The randomization was stratified according to four factors: clinical tumor size (T2 versus ≥T3), clinical nodal status (N0-1 versus ≥N2), estrogen receptor (ER) and/or progesterone receptor (PgR) ( positive versus negative) and whether a patient was a candidate for BCS (yes versus no). The main analysis indicated that all factors were evenly distributed across the three treatment arms, except for the tumor size, in which more ≥T3 tumors were randomly assigned to the trastuzumab only arm (53%) compared with the lapatinib only arm (38.3%) and the combination arm (35.5%).
In the current analysis, we investigated the association between the type of surgery and the different clinicopathological factors, which were as follows: age, histological subtype, histological grade, clinical tumor size, ER status and tumor multicentricity/multifocality. This is in addition to the response to treatment (both radiological and clinical) and the country where the treatment was administered. Countries were classified as developed or developing; the former being defined as high-income countries as per the classification of the Organization for Economic Cooperation and Development (OECD) (www.oecd.org).
We evaluated the association between the type of actual surgery carried out and the clinicopathological factors, and preoperative response to treatment using Mann-Whitney or Kruskal-Wallis, as appropriate. A logistic regression model relating the probability of BCS to the candidate predictors and the treatment arms was carried out in order to identify whether any of the clinicopathological factors was associated with BCS and whether adjustment for these predictors changes the apparent relationship between the treatment arm and BCS. We fitted the model including all factors with and without the type of planned surgery at diagnosis, adjusting for the treatment arm. Finally, we evaluated the factors that could be related to the type of planned surgery at diagnosis. All the statistical analyses were carried out by Frontier Science (Scotland).
results
A total of 455 patients in 23 countries were enrolled in the NeoALTTO trial. Of those, 26 patients did not undergo breast surgery and hence, were excluded from this analysis. Table 1 shows the association and distribution of the different clinicopathological factors, response to treatment (clinical and radiological) and the type of actual surgery carried out. BCS was less common in patients treated in developing countries (P < 0.0001), initially planned for mastectomy at the time of diagnosis (P < 0.0001), had multifocal/multicentric tumors (P = 0.007), unknown histological grade (P = 0.02), ER-negative tumors (P = 0.005), tumors >5 cm before initiation of neoadjuvant therapy (P < 0.0001) and a residual palpable mass at the pre-surgery visit (P = 0.0001). No association between the type of surgery and age (P = 0.38), histological subtype (P = 0.95), and preoperative radiological response (P = 0.86) was observed. Strikingly, out of 68 and 199 patients showing a complete and partial radiological response before surgery, 52.9% and 55.3% were subjected to mastectomy, respectively. Table 2 shows the logistic regression model taking into account all possible confounding factors, including the type of planned surgery at diagnosis. As expected, we found that patients who were initially planned for BCS were nearly five times more likely to undergo BCS compared with patients who were initially planned for mastectomy or were considered ineligible for resection at diagnosis [OR: 5.46 (95% CI, 3.17-9.41), P < 0.0001]. Moreover, patients who had a tumor >5 cm at baseline were more likely to be offered mastectomy [OR: We did not observe any effect of age, histological grade, radiological response or completion of therapy on the decision of surgery. These associations were observed independent of the treatment arm (P = 0.41).
In order to understand the effect of the individual factors independent of the type of planned surgery before starting neoadjuvant therapy, we repeated the same model excluding planned surgery (Table 3 ). In addition to the formerly observed associations, we found that patients in developed countries were clearly more likely to be managed with BCS [OR: 2.27 (95% CI, 1.43-3.61), P = 0.0004] independent of the treatment arm (P = 0.385).
Finally, we evaluated the association between the different baseline characteristics and the type of planned surgery before 
discussion
In this study, we evaluated the factors associated with surgical management following neoadjuvant therapy in patients enrolled in the NeoALTTO trial. We found that the type of planned surgery at diagnosis, tumor multicentricity, ER status, tumor size at baseline and the presence of residual tumor on breast palpation were the main determinants of the type of the surgery that was carried out following neoadjuvant therapy. The type of planned surgery itself was influenced by obvious factors such as tumor size, but also by the geographic region. Strikingly, the radiological response to treatment appeared to have played no role in the surgical decision. This highlights a negative attitude that may deny a large fraction of women the chance of preserving their breast, with no clinical reasons that justify this decision. For nearly three decades, we have sufficient evidence supporting that a BCS followed by radiotherapy is as effective as mastectomy in terms of local control, disease-free and overall survival in newly diagnosed breast cancer patients [18, 19] . However, evidence is less clear regarding the role of BCS following neoadjuvant therapy. Nevertheless, several studies point out that patients managed with BCS after neoadjuvant therapy have an acceptably low rate of locoregional recurrences [20] [21] [22] [23] [24] [25] . Such an approach has been further endorsed by several groups as well [3, 4] and is currently widely accepted, in the absence of classic contraindications to BCS. Accordingly, improvements in neoadjuvant therapies are expected to have a positive impact on breast conservation rates. However, this did not appear to be the case in our study.
Patients with ER-negative tumors were less likely to have a BCS compared with patients with ER-positive disease. This was observed independent of other important factors like tumor stage, tumor multicentricity, response to treatment or even the type of planned surgery at diagnosis. This is a major concern as ER-negative tumors are highly responsive to chemotherapy in the neoadjuvant setting. Interestingly, across the four neoadjuvant trials testing the role of dual HER2 blockade, the pCR rates were significantly higher in the ER-negative patient population, despite being all HER2-positive. Hence, such attitude would deny the most suitable patient population for the neoadjuvant approach the chance to preserve their breast, which is so far the main advantage for preoperative therapy. Indeed, it is not clear why patients with ER-negative tumors were less considered for BCS. It appears that the known aggressive nature of ER-negative tumors contributed to such decision, which underscores that BCS is perceived as an inferior option to mastectomy in this patient population, a conception that is not supported by evidence and, in our opinion, should be challenged.
At diagnosis, the tumor size appeared to influence the type of surgery that the patient is eligible to undergo, which is expected. However, we noticed that patients treated in Arm A, lapatinib alone arm; Arm B, trastuzumab alone arm; Arm C, combined lapatinib and trastuzumab arm.
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developing countries were more likely to be assigned to mastectomy independent of the presence of advanced tumor stage at diagnosis. This could be attributed to the lack of optimal radiotherapy services in some of these countries [26] . Another possible reason could be the fact that breast cancer patients are less likely to be managed within multidisciplinary teams in the developing world [27, 28] . Hence, the lack of communication between the medical and surgical teams in such cases could considerably affect the surgical decision. The introduction of BCS and later sentinel lymph node biopsy has resulted in tremendous improvement in the quality of life of millions of women, who were spared aggressive mutilating surgeries [29] . While we have limited long-term data on the outcome of BCS after neoadjuvant therapy, we believe that modern breast cancer surgery should orientate its strategy focusing mainly on post-treatment outcomes rather than the baseline tumor characteristics. We believe that our results call for a clear consensus on the role of BCS in patients responding to neoadjuvant therapy. This issue highlights the importance of multidisciplinary discussions and the need for mutual collaboration between the medical and surgical teams, particularly in the neoadjuvant setting. This will translate the progress in neoadjuvant therapies into improved breast conservation rates, which would positively impact patient's quality of life and overall patient care. 
